- CPSC Warns Against Using Peloton Treadmill After Child’s Death
- AHA News: Sorting Folklore From Fact on the Health Benefits of Garlic
- Are You Eating Foods That Harm Your ‘Microbiome’?
- Are You Eating Foods That Harm Your ‘Microbiome’?
- Half of American Adults Have Now Gotten at Least One COVID Vaccine Shot
- Many Employees Have Mixed Feelings as Offices Reopen
- In Breast Cancer Survivors, Obesity Raises Odds for Cancer’s Return
- Is It Allergies or COVID? Expert Shows How to Tell the Difference
- Health Highlights, April 19, 2021
- Common MS Meds Might Be Less Effective in Black Patients
Hetlioz Approved for Sleep Disorder in Blind People

Hetlioz (tasimelteon) has been approved by the U.S. Food and Drug Administration to treat a sleep condition caused by a completely blind person’s inability to regulate the body clock by recognizing light from dark.
The condition is called non-24-hour sleep wake disorder. Affected people may have difficulty falling asleep or staying asleep, and may become groggy, the agency said Friday in announcing the approval.
Up to 100,000 people in the United States have the disorder, the FDA said in a news release.
The safety and effectiveness of the new drug were evaluated in a clinical study of 104 completely blind people. Reported side effects included headache, elevated liver enzymes, unusual dreams and infections of the upper respiratory or urinary tract.
The drug is produced by Vanda Pharmaceuticals, based in Washington, D.C.
More information
Visit the FDA to learn more.
Source: HealthDay